Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00795158
First received: November 20, 2008
Last updated: May 4, 2015
Last verified: May 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2004
  Primary Completion Date: January 2004 (Final data collection date for primary outcome measure)
Publications:
Seidenari S, Cirillo A, Amoroso S, Flori ML, Amerio P, Ricciuti E, Vena GA, Berardesca E, Le Grazie C and the Italian Study Group on Desloratadine (DL) in Chronic Urticaria. Desloratadine 5 milligrams once daily improves quality of life in chronic idiopathic urticaria. G Ital Dermatol Venereol. 2006;141(3):207-214